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Background: We investigated whether combinations of serum cytokines, used with logistic disease predictor
models, could facilitate the detection of pancreatic ductal adenocarcinoma (PDAC).
Methods: The serum levels of 27 cytokines were measured in 241 subjects, 127 with PDAC, 49 with chronic
pancreatitis, 20 with benign biliary obstruction and 45 healthy controls. Samples were split randomly into
independent training and test sets. Cytokine biomarker panels were selected by identifying the top performing
cytokines in best fit logistic regression models during multiple rounds of resampling from the training dataset.
Disease prediction by logistic models, built using the resulting cytokine panels, was evaluated with training and test
sets and further examined using resampled performance evaluation.
Results: For the discrimination of PDAC patients from patients with benign disease, a panel of IP-10, IL-6, PDGF plus
CA19-9 offered improved diagnostic performance over CA19-9 alone in the training (AUC 0.838 vs. 0.678) and
independent test set (AUC 0.884 vs. 0.798). For the discrimination of PDAC from CP, a panel of IL-8, CA19-9, IL-6 and IP-10
offered improved diagnostic performance over CA19-9 alone with the training (AUC 0.880 vs. 0.758) and test set
(AUC 0.912 vs. 0.848). Finally, for the discrimination of PDAC in the presence of jaundice from benign controls with
jaundice, a panel of IP-10, IL-8, IL-1b and PDGF demonstrated improvement over CA19-9 in the training (AUC 0.810 vs.
0.614) and test set (AUC 0.857 vs. 0.659).
Conclusions: These findings support the potential role for cytokine panels in the discrimination of PDAC from patients
with benign pancreatic diseases and warrant additional study.
Keywords: Pancreatic cancer, Biomarker, Cytokine, CA19-9, IP-10, IL-8 and PDGFIntroduction
Novel biomarkers for use in disease detection and/or
treatment are urgently needed to improve outcomes for
patients with pancreatic cancer (PDAC) [1,2]. Supplement-
ing current diagnostic modalities with biomarker detection
in blood [3] could potentially enhance PDAC diagnosis. At
present, the only serum biomarker in routine clinical use
for PDAC is CA19-9 [4-6]. The ability of novel biomarkers
to accurately detect PDAC depends on their capacity to* Correspondence: ecostell@liverpool.ac.uk
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unless otherwise stated.discriminate PDAC from benign diseases of the pancreas,
such as chronic pancreatitis. In addition, a majority of
PDAC patients present with tumours involving the pan-
creatic head, which leads to obstructive jaundice [7]. The
differentiation of PDAC in jaundiced patients from benign
obstructive jaundice due to choledocholithiasis or chronic
pancreatitis is a major clinical challenge.
CA19-9 is a sialyated Lewis blood group cell surface
carbohydrate antigen, expressed in normal pancreatic
ductal cells in around 95% of the population which express
the Lewis antigen glycosyltransferase enzyme. CA19-9 is
shed into the general circulation and is commonly used in
clinical practice to monitor patients with PDAC [4,5,8-10].
CA19-9 is also secreted in a mucin bound form by thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in bile [11]. Serum levels of CA19-9 are elevated in patients
with chronic pancreatitis and benign biliary obstruction to
a similar extent as in patients with smaller pancreatic can-
cers [4,8]. Consequently the overall accuracy of CA19-9 for
the diagnosis of PDAC is reduced but there is also the op-
portunity to enhance the specificity of CA19-9 in combin-
ation with other tumour-associated biomarkers [12-17].
Mediators of the tumour microenvironment and the host
response [12-15,18] and notably cytokines involved in
the immune system, inflammation, tumour development
and metastasis [19,20] are emerging as key candidate
biomarkers. While single cytokines lack sensitivity and
specificity for accurate cancer detection [21], specific com-
binations may prove valuable as markers.
Cytokine biomarker panels for the discrimination of
specific patient groups were selected by identifying the
best logistic regression models during multiple rounds
of resampling [22] from a training dataset. The resulting
optimum panels were evaluated using logistic regression
models in both training and independent test sets before
further subjecting panels to resampling performance
evaluation. We discovered a unique panel of cytokines
that improved the performance of CA19-9 for the dis-
crimination of PDAC patients from patients with benign
pancreatic disease. Moreover, in the presence of jaun-
dice, whilst CA19-9 offered relatively poor discrimin-
ation of PDAC patients from benign disease patients, a
panel made up solely of cytokines afforded significantly
better discrimination.
Results
Cytokine levels in patients diagnosed with PDAC, chronic
pancreatitis and benign biliary obstruction and healthy
subjects
Filtering of the entire dataset showed that serum levels
of nine cytokines, comprising PDGF, IL-1b, IL-1ra, IL-6,
IL-8, Eotaxin, IP-10, MCP-1 and MIP-1b, were signifi-
cantly different between PDAC in comparisons with one
or more of the control variants (Table 1). Serum levels
of five cytokines, IL-1ra, IL-6, IL-8, IP-10 and MIP-1b,
as well as serum CA19-9 levels were significantly in-
creased in PDAC compared to HCs. Of these, CA19-9,
IL-8 and IP-10, were also significantly elevated in PDAC
compared to patients with CP, whilst a comparison of
PDAC versus BBO revealed significant increases in
serum levels of Eotaxin, IL-1b, MIP-1b and PDGF
(Table 1). Serum levels of CA19-9, IL-8, IP-10, MIP-1b
and PDGF, were significantly elevated in patients with
PDAC compared to patients with benign disease
(Table 1). Comparison of serum cytokine levels in sub-
jects with obstructive jaundice showed that IL-8, IP-10,
MIP-1b, PDGF and CA19-9 were all significantly ele-
vated in PDAC compared to controls (Table 2). Thecirculating median levels of cytokines and CA19-9 (i.e.
un-normalised) are shown in Additional file 1: Table S1.
Spearman’s Rank analysis of the cytokines incorporated
into panels and CA19-9 for each group showed a max-
imum Rho of 0.361, indicating no correlation between
age and analyte level.
Classification model to distinguish patients with PDAC
from healthy subjects
In the training dataset (84 PDAC, 29 HCs), serum
CA19-9 had a very high performance in distinguishing
patients with PDAC from healthy subjects (AUC = 0.925,
CI = 0.876-0.974). Serum levels of IL-8 and IL-1b were
also both found with high frequency in top ranked
models of the training set in successive resamples
(100% and 95% respectively) as well as CA19-9 (99%)
(Figure 1A). The combined panel comprising IL-8, IL-1b
and CA19-9 showed a statistically significant improve-
ment in accuracy over CA19-9 alone (AUC = 0.984, CI =
0.968-1.00 vs. AUC = 0.925, CI = 0.876-0.974; p = 0.004;
Figure 1B), although diagnostic improvement of the
panel over CA19-9 was not statistically significant in the
test set (PDAC = 43, HC = 16) (AUC = 0.997, CI = 0.990-
1.00 vs. AUC = 0.975, CI = 0.932-1.00) (Figure 1C). Re-
sampling the combined dataset (PDAC = 127, HC = 45)
100 times however, showed a statistically significant im-
proved accuracy for the panel compared to CA19-9
alone (median = 94.6%, IQR = 93.8-96.4% vs. median =
89.3%, IQR = 88.4-91.1% respectively; Friedman test p <
0.001). The SN (median = 94.1%, IQR = 91.8-96.4%, ver-
sus 85.9%, IQR = 84.7-89.4% respectively) and SP (me-
dian = 100%, IQR = 96.3-100% versus median = 96.3%,
IQR = 96.3-97.2%) of the panel on resampling were also
significantly higher than resampled CA19-9 alone (both
Friedman test p < 0.001; Figure 1D).
Classification model to distinguish patients with PDAC
from patients with benign disease
Model building using the training set (PDAC = 84, be-
nign disease = 45) to distinguish PDAC patients from pa-
tients with benign pancreatic disease showed that the
most frequent cytokines in top ranked resampled models
were IL-8 (98%), IP-10 (76%), IL-6 (56%) and PDGF
(36%) plus CA19-9 (22%) (Figure 2A). As a panel, these
cytokines demonstrated improved diagnostic perform-
ance over CA19-9 alone (AUC = 0.838; CI = 0.768-0.909
vs. AUC = 0.678; CI = .579-0.776; p < 0.001) (Figure 2B)
with significantly improved SN (median = 92.9%, CI =
85-97% vs. median = 53.6%, CI = 42-65%, respectively,
p < 0.001), but significantly reduced SP (median = 57.8%,
CI = 42-72% vs. median = 84.4%, CI = 71-94% respectively,
p = 0.008). Using the independent test data (PDAC =
43, benign disease = 24), the panel showed improved
performance over CA19-9 alone (AUC = 0.884, CI =
Table 1 Normalised cytokine data in the combined training and test datasets
Median (95% CI) P value
Analyte PDAC (n = 127) HC (n = 45) CP (n = 49) BBO (n = 20) CP + BBO (n = 69) PDAC vs. HC PDAC vs. CP PDAC vs. BBO PDAC vs. CP + BBO
CA19-9 0.01 −5.01 −2.7 −0.82 −2.25 <0.001 <0.001 NS <0.001
(−1.0 to 0.2) (−5.4 to −4.6) (−3.5 to −2.2) (−2.6 to 0.5) (−3.2 to −1.6)
Eotaxin 0.48 0.23 0.53 −0.08 0.45 NS NS <0.05 NS
(0.3 to 0.6) (−0.2 to 0.5) (0.2 to 0.8) (−0.5 to 0.7) (−0.03 to 0.7)
IL-1b 0.23 0.16 0.27 0.14 0.17 NS NS <0.05 NS
(0.1 to 0.4) (0.08 to 0.3) (0.04 to 0.6) (−0.5 to 0.5) (0.05 to 0.4)
IL-1ra 0.72 0.18 0.78 0.06 0.59 <0.05 NS NS NS
(0.4 to1.0) (−0.3 to 0.4) (0.4 to 1.3) (−1.5 to 1.5) (0.2 to 1.0)
IL-6 1.25 0.41 1.65 1.78 1.71 <0.001 NS NS NS
(1.0 to 1.5) (0.1 to 0.7) (1.2 to 2.1) (1.0 to 2.5) (1.2 to 2.0)
IL-8 0.95 0.02 0.54 0.38 0.51 <0.001 <0.001 NS <0.001
(0.8 to1.2) (−0.3 to 0.06) (0.3 to 0.8) (−0.4 to 1.1) (0.3 to 0.8)
IP-10 −1.85 −2.99 −2.6 −2.52 −2.59 <0.001 <0.001 NS <0.001
(−2.0 to −1.7) (−3.3 to −2.7) (−2.9 to −2.3) (−2.9 to −1.5) (−2.8 to −2.3)
MCP-1 0.31 0.44 0.92 0.64 0.81 NS NS NS NS
(0.2 to 0.6) (−0.02 to 0.6) (0.3 to 1.2) (−0.2 to 1.6) (0.3 to 1.2)
MIP-1b 0.31 −0.45 0.02 −0.28 −0.06 <0.001 NS <0.05 <0.01
(0.2 to 0.4) (−0.6 to −0.2) (−0.3 to 0.4) (−0.5 to 0.2) (−0.3 to 0.2)
PDGF 0.44 0.31 0.21 −0.62 0.09 NS NS <0.01 <0.01
(0.2 to 0.5) (0.1 to 0.4) (−0.02 to 0.5) (−1.5 to 0.2) (−0.18 to 0.4)
Median normalised log2 transformed data are presented for each analyte; the 95% CI are given in brackets. PDAC = Cancer, CP = Chronic Pancreatitis, BBO = Benign Biliary Obstruction. Wilcoxon signed rank tests were

















Table 2 Cytokine data from patients with biliary obstruction (cancer and benign) in the combined training and test datasets
Analyte Median (95% CI) PDAC
with biliary obstruction
(n = 83)
Median (95% CI) BBO plus
CP with biliary obstruction
(n = 27)
P Value
PDAC with biliary obstruction vs.
Obstructed BBO plus CP with biliary
obstruction




PDAC with biliary obstruction vs. PDAC
without biliary obstruction PDAC
CA19-9 0.16 −1.10 <0.05 −1.06 <0.05
(−0.6 to 0.4) (−2.3 to −0.5) (−1.8 to 0.1)
Eotaxin 0.48 0.40 NS 0.51 NS
(0.2 to 0.6) (−0.3 to 0.7) (0.2 to 0.8)
IL-1b 0.23 0.25 NS 0.24 NS
(0.1 to 0.4) (0.03 to 0.4) (0.002 to 0.4)
IL-1ra 0.72 0.33 NS 0.79 NS
(0.4 to 1.0) (−0.8 to 1.0) (0.2 to 1.3)
IL-6 1.38 1.97 NS 0.92 NS
(1.2 to 1.7) (1.0 to 2.4) (0.7 to 1.3)
IL-8 0.96 0.39 <0.05 0.89 NS
(0.8 to 1.4) (0.2 to 1.1) (0.5 to 1.2)
IP-10 −1.79 −2.59 <0.05 −2.06 NS
(−2.0 to −1.6) (−2.8 to −2.2) (−2.5 to −1.7)
MCP-1 0.26 0.56 NS 0.40 NS
(0.05 to 0.6) (0.001 to 1.4) (0.08 to 0.8)
MIP-1b 0.34 −0.06 <0.05 0.29 NS
(0.2 to 0.5) (−0.5 to 0.3) (−0.09 to 0.35)
PDGF 0.42 −0.27 <0.01 0.51 NS
(0.2 to 0.5) (−0.9 to 0.4) (0.1 to 0.7)
Median normalised log2 transformed data are presented for each analyte; the 95% CI are given in brackets. PDAC = Cancer, CP = Chronic Pancreatitis, BBO = Benign Biliary Obstruction. Wilcoxon signed rank tests were

















Figure 1 Classification of patients with PDAC vs. healthy control individuals. A. Feature finding showing the percentage occurrence of
cytokines in models following resampling of training data for PDAC vs. Healthy Control. B. Training set ROC Curves for PDAC vs. Healthy Control
for a panel of IL-8, CA19-9 and IL-1b versus CA19-9 alone. C. Test set ROC curves for PDAC vs. Healthy Control for the panel of IL-8, CA19-9 and
IL-1b versus CA19-9. D. The resampling performance of the panel of IL-8, CA19-9 and IL-1b versus CA19-9 for the classification of PDAC vs.
Healthy Control. The accuracies, sensitivities and specificities of the panel compared to CA19-9 alone over 100 patient-balanced resamples is
shown. The quantiles of the performance indicators are summarised as boxplots with individual points superimposed and the significance of
Friedman test comparisons is indicated (***p <0.001).
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p = 0.058) (Figure 2C) with a median SN of 81.4% (CI =
67-92%) and SP of 91.7% (CI = 73-99%) for the panel
compared to 88.4% (CI = 75-96%) and 66.7% (CI = 45-
84%) respectively for CA19-9 alone. The inconsistency
in the outcomes with training and test set data here il-
lustrate the problems associated with diagnostic per-
formance assessment using single data splits.
Resampling of the combined dataset (PDAC = 127, be-
nign disease n = 69) (Figure 2D) generated 100 independ-
ent optimum values for SN, SP and accuracy and showed
that the accuracy of the cytokine panel (median = 77.8%,
IQR = 75.6-79.4%) was significantly improved compared
to CA19-9 alone (median = 67.9%, IQR = 64.1-72.5%;
Friedman test p < 0.001). The SP of the cytokine panel
(median = 84.8%, IQR = 80.4-89.1%) was significantly
better than that of CA19-9 alone (median = 78.2%,
IQR = 58.7-84.8%; Friedman test p < 0.001), while theimprovement in SN was not statistically significant
(median = 74.7%, IQR 70.6-77.9% vs. median = 58.8%,
IQR = 52.9-80.0% respectively; Friedman test p = 0.071)
(Figure 2D).
Classification model to distinguish patients with PDAC
from patients with chronic pancreatitis
Optimum cytokine combinations for the discrimination of
PDAC from CP with the training set (PDAC= 84 and
CP = 32) showed that the most frequent cytokines in
resampled models were IL-8 (97%), IL-6 (63%) and IP-10
(54%) as well as CA19-9 (77%) (Figure 3A). A panel com-
prising IL-8, IL-6 and IP-10 with CA19-9, showed a signifi-
cantly improved diagnostic performance with the training
data over CA19-9 alone (AUC= 0.880, CI = 0.818-0.943 vs.
AUC = 0.758, CI = 0.668-0.849; p = 0.005) (Figure 3B).
The SN of the panel (median = 75.0%, CI = 64-84%) was
significantly better than CA19-9 alone (median = 53.6%,
Figure 2 Classification of patients with PDAC vs. patients with benign disease. (A) Feature finding results showing the percentage
occurrence of cytokines in models following resampling of training data for PDAC vs. benign disease. (B) Training set ROC Curves for PDAC vs.
benign disease for a panel of IL-8, IP-10, IL-6, PDGF and CA19-9 versus CA19-9 alone. (C) Test set ROC curves for PDAC vs. benign disease for the
panel of IL-8, IP-10, IL-6, PDGF versus CA19-9. (D) The resampling performance of the panel of IL-8, IP-10, IL-6, PDGF and CA19-9 versus CA19-9
for the classification of PDAC vs. benign disease. The accuracies, sensitivities and specificities of the panel compared to CA19-9 alone over 100
patient-balanced resamples is shown. The quantiles of the performance indicators are summarised as boxplots with individual points
superimposed and the significance of Friedman test comparisons is indicated (***p < < 0.001).
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(median = 90.6%, CI = 75-98% vs. median = 96.9%, CI =
84-100%, respectively). In the independent test set
(PDAC = 43, CP = 17), the AUC achieved with the panel
was greater than that of CA19-9 (0.912; CI 0.838-0.987
vs. AUC 0.848; CI 0.728-0.968, respectively) (Figure 3C).
Resampling the combined dataset (PDAC = 127 and
CP = 49) revealed a significant improvement in accuracy
with the cytokine panel (median = 79.5%, IQR = 77.8-
82.1%) compared to CA19-9 (median = 73.5%, IQR =
64.7-76.1%; Friedman test p < 0.001) (Figure 3D). The SP
was also significantly better (median = 90.9%, IQR =
87.9-93.9% vs. median = 78.8%, IQR = 69.7-93.9% re-
spectively; Friedman test p < 0.001) with no significant
difference in SN estimates (median = 76.2%, IQR = 72.6-
78.6% vs. median = 73.8%, IQR = 52.3-78.6%, respectively;
Friedman test p = 0.053).Classification model in patients with obstructive jaundice
to distinguish patients with PDAC from patients with
benign disease
The training dataset of patients with serum bilirubin
levels ≥ 20 μmol/L (PDAC= 55, benign disease = 18) was
resampled and the top ranked regression models most fre-
quently featured were IP-10 (65.4%), IL-8 (50.0%), IL-1b
(41.0%) and PDGF (41.0%) whilst CA19-9 was the feature
of lowest importance (6.1%) (Figure 4A). The cytokine
panel (IP-10,IL-8,IL-1b and PDGF) was significantly more
accurate than CA19-9 (AUC= 0.810, CI = 0.693-0.927 vs.
AUC= 0.614, CI = 0.445-0.782; p = 0.023) (Figure 4B) with
significantly improved SN (median = 87.3%, CI = 76-95% vs.
median = 63.6%, CI = 50-76% respectively; p < 0.001) and
unchanged SP (median = 66.7%, CI = 41-87% vs. median =
66.7%, CI = 41-87%, respectively). The test set of samples
with serum bilirubin levels ≥ 20 μmol/L (PDAC= 28,
Figure 3 Classification of patients with PDAC vs patients with chronic pancreatitis. (A) Feature finding results showing the percentage
occurrence of cytokines in models following resampling of training data for PDAC vs. chronic pancreatitis. (B) Training set ROC Curves for PDAC
vs. chronic pancreatitis for a panel of IL-8, CA19-9, IL-6, IP-10 versus CA19-9 alone. (C) Test set ROC curves for PDAC vs. chronic pancreatitis for
the panel of IL-8, CA19-9, IL-6 and IP-10 and CA19-9 alone. (D) The resampling performance of the panel of IL-8, CA19-9, IL-6, IP-10 versus CA19-9
for the classification of PDAC vs. chronic pancreatitis. The accuracies, sensitivities and specificities of the panel compared to CA19-9 alone over
100 patient-balanced resamples is shown. The quantiles of the performance indicators are summarised as boxplots with individual points
superimposed and the significance of Friedman test comparisons is indicated (***p < < 0.001).
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(AUC= 0.857, CI = 0.699-1 vs. AUC= 0.659, CI = 0.426-
0.892 respectively) (Figure 4C).
Resampling the combined dataset of patients with serum
bilirubin levels ≥ 20 μmol/L (PDAC= 83 and benign dis-
ease = 27) generated 100 independent optimum values and
showed significantly greater accuracy with the panel over
CA19-9 (median = 73.9%, IQR = 68.5-80.8% vs. median =
63.7%, IQR = 60.3-75.3%, respectively; Friedman test p <
0.001) (Figure 4D). In particular, the SN for the cytokine
panel was significantly higher than that of CA19-9 alone
(median = 74.5%, IQR = 63.6-85.9% vs. median = 61.8,
IQR = 54.5-85.4%, respectively; Friedman test p = 0.002).
Ability to detect resectable PDAC and advanced PDAC
cases
The study included samples from both resectable and ad-
vanced PDAC cases (Additional file 1: Table S1). Binomiallogistic modelling did not identify cytokines that distin-
guished between these two disease categories in either the
training or test sets. However, post hoc tests showed that
advanced and resectable PDAC were equally likely to be de-
tected in our models as there was no significant difference
in the proportion of advanced and resectable cases detected
in pooled training and test set data (Pearson chi squared
test for equality of proportion of detections of advanced
and resectable PDAC at df =1; PDAC vs. HC, p = 0.997;
PDAC vs. Benign Disease, p = 0.417; PDAC vs. CP, p =
0.704 and PDAC with obstructive jaundice vs. Benign Dis-
ease with obstructive jaundice, p = 0.892).
Discussion
The accurate diagnosis of PDAC against a complex
range of primary secondary and even tertiary health care
scenarios remains a major clinical challenge. More spe-
cifically the clinical settings in which biomarker panels
Figure 4 Classification of patients with PDAC in the presence of jaundice vs. patients with benign disease in the presence of jaundice. (A)
Feature finding results showing the percentage occurrence of cytokines in models following resampling of training dataset for PDAC patients with high bilirubin
vs. patients with benign disease and high bilirubin. (B) Training set ROC Curves for PDAC patients with high bilirubin vs. patients with benign disease and high
bilirubin for a panel of IP-10, IL-8, IL-1b, PDGF and CA19-9 versus CA19-9 alone. (C) Test set ROC curves for PDAC patients with high bilirubin vs. patients with
benign disease and high bilirubin for the panel of IP-10, IL-8, IL-1b, PDGF, CA19-9 compared to CA19-9 alone. (D) The resampling performance of the panel
and CA19-9 for the classification of high bilirubin PDAC vs. high bilirubin benign disease. The accuracies, sensitivities and specificities of the panel IP-10,
IL-8, IL-1b, PDGF, CA19-9 compared to CA19-9 alone over 100 patient balanced resamples is shown. The quantiles of the performance indicators are
summarised as boxplots with individual points superimposed and the significance of Friedman test comparisons is indicated (***p < < 0.001).
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depending on whether the disease is asymptomatic or
symptomatic, and whether jaundice is present or absent.
Thus, improving diagnosis involves discriminating pa-
tients with pancreatic cancer from patients with benign
diseases of the pancreas or the biliary system. In this
study, we used advance logistic modeling to determine
how reliably distinct combinations of cytokines could fa-
cilitate differential pancreatic cancer diagnosis.
The performance of CA19-9 for the discrimination of
PDAC patients from healthy subjects is variable, with
some studies reporting just acceptable AUC values of
0.83-0.84 [15,23], while one study an accuracy as high as
AUC = 0.90 [24]. In this study we observed a very strong
performance from CA19-9 compared to healthy con-
trols, providing an AUC >0.92 in both training and test
sets and very high median resampled estimates ofoptimum SN and SP were 85.9% and 96.3% respectively.
The addition of two cytokines (IL-8 and IL-1b) to
CA19-9 in a panel enhanced the performance of CA19-
9, increasing the median resampled accuracy from 89%
to 95% while the median resampled SN and SP was in-
creased to 94% and 100%, respectively. This supports the
finding by Ebrahimi et al. [25] who found that IL-8 was
increased in serum from PDAC patients compared to
healthy controls, as was IL-1ra and IL-6, although these
cytokines did not form part of the final panel.
The cytokines IL-8, IP-10, IL-6 and PDGF emerged as
the strongest candidates in discriminating patients with
PDAC from patients with benign pancreatic disease and
combining these cytokines with CA19-9 afforded en-
hanced discrimination. The inconsistent outcomes with
the training and test set data in this case illustrate the
potential problems of overfitting and bias associated
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http://www.molecular-cancer.com/content/13/1/114with single data splits, and supports the use of resam-
pling for a more robust estimate of performance. It is
notable that the SN and SP estimates with CA19-9 dur-
ing resampling were bi-modal while the panel-derived
estimates were uniformly distributed (Figure 2D). This
suggested that the performance of CA19-9 alone was
less uniform and therefore less reliable than the per-
formance of the cytokine panel. Interestingly, a similar
bi-modal distribution, resulting in an increase in the
range of SN and SP estimates with CA19-9 compared to
cytokine panels, was observed with resampled PDAC
versus CP (Figure 3D), and with resampled High Biliru-
bin PDAC versus High Bilirubin Benign Disease patients
(Figure 4D). This suggests that the panels in general pro-
vided a more reliable performance than CA19-9 alone.
Whilst CA19-9 levels were significantly raised in patients
with biliary obstruction as might be expected [10,26,27] the
levels of individual cytokines in cancer patients were not as-
sociated with jaundice. In discriminating jaundiced patients
with PDAC from jaundiced patients with benign pancreatic
disease, CA19-9 alone, performed poorly. IP-10, IL-8, IL-1b
and PDGF, which were all significantly elevated in jaun-
diced patients with PDAC compared to jaundiced patients
with benign disease, enabled significantly better discrimin-
ation of these two groups when used in combination. Even
though obstructive jaundice occurs relatively late in pancre-
atic cancer, this can wane so more efficient and accurate
differential diagnosis of these patients is of considerable im-
portance in routine clinical practice. IL-8 levels are elevated
in PDAC patients [15,28] and this pro-inflammatory cyto-
kine was a prominent feature as a discriminator for PDAC
in all of the panels in this study. It is produced in mono-
cytes and endothelial cells, and a variety of tumours [28-30]
and high serum levels of IL-8 in PDAC are linked to poor
survival [31].
IP-10 featured in all disease comparison panels for
diagnosis, consisitent with a previous small study in
PDAC [32] and a study in colorectal cancer [33]. In-
creased expression of IP-10 and its receptor CXCR3
have also been associated with several advanced human
cancers, including ovarian cancer, malignant melanoma,
mutliple myeloma and basal cell carcinoma [34]. Whilst
IP-10 generally performed well in the discrimination of
PDAC from patients with benign disease, it was the best
performing analyte for the discrimination of PDAC pa-
tients with jaundice from patients with benign disease in
the presence of jaundice. This pro-inflammatory chemo-
kine has also been shown to be secreted from several
cell types in response to IFN-γ, and attracts activated
lymphocytes, monocytes and NK cells to sites of inflam-
mation [34], inhibits angiogenesis and promotes the sur-
vival and proliferation of tumour-specific T-cells [34-36].
IL-6 levels were observed to be significantly elevated
in patients with PDAC compared to healthy controls,although it did not perform well enough to be part of
the cytokine panel [25,37,38]. This cytokine was import-
ant in the discrimination of PDAC from chronic pan-
creatitis where it was the third most important analyte
after IL-8 and CA19-9, during feature finding. It had
limited value in distinguishing PDAC patients from pa-
tients with jaundice due to benign disease. IL-6 is a pro-
imflamatory cytokine that it involoved in the recruit-
ment of neutrophils and stimulating T-cell proliferation
and migration [39]. High serum levels of IL-6 have been
shown in many different cancer types, and positive asso-
ciations with tumour stage, size and disease progression
have been reported [39]. PDGF levels were not signifi-
cantly different between patients with PDAC, patients
with chronic pancreatitis and healthy subjects. Signifi-
cantly decreased serum levels of PDGF were observed
in patients with jaundice due to benign disease and may
account for the discrimination of cancer patients from
patients with biliary obstruction.
Other groups have examined the ability of cytokine
panels to detect PDAC. Zeh et al. [40] used LabMAP
serum technology with classification trees to identify panels
to distinguish pancreatic cancer patients from chronic pan-
creatitis patients or control subjects. Interestingly their
study identified IP-10 and IL-8 as having ability to discrim-
inate PDAC from these two groups [40]. This is consistent
with our study in which IL-8 was the best performing cyto-
kine to distinguish PDAC cases from healthy controls and
IP-10 and IL-8 were both featured in models distinguishing
pancreatic cancer from benign disease. More recently,
Dima et al. [31] explored the levels of circulating inflamma-
tory cytokines in a small number of pancreatic cancer pa-
tients and controls. The study identified high levels of IL-6
in PDAC cases compared to chronic pancreatitis patients
and elevated IL-10 and TNFα in PDAC cases compared to
healthy subjects [31].
This study has a number of limitations. The sample
sizes for investigating the effect of obstructive jaundice
on performance were small, especially in the test data-
sets. In addition, the study suffered the loss of a number
of analytes due to large coefficients of variance. Analytes
such as IL-2, IL-15, and MIP-1a were present at very
low concentrations and undetectable in more than half
of the subjects studied. As expected the coefficient of
variation was higher for analytes measured at lower con-
centrations on the Luminex platform compared to those
measured at higher concentrations [41]. The diagnostic
potential of these analytes should be tested under condi-
tions sensitive to lower concentrations. Finally, we have
confined this study to evaluating the potential of serum
cytokine panels for pancreatic cancer diagnosis. The re-
lationship between serum cytokine levels and prognosis
is worthy of study, although lies outside the scope of this
manuscript.
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In summary, we show that for the discrimination of pa-
tients with PDAC from patients with benign disease,
combining IL-8, IP-10, IL-6 and PDGF with CA19-9 was
better than using CA19-9 alone. Moreover, whilst CA19-
9 was ineffective at discriminating between jaundiced
PDAC patients versus jaundiced controls, a panel con-
taining IP-10, IL-8, IL-1b and PDGF provided good dis-
crimination. These findings support the potential role
for specific cytokines in the differential diagnosis of pan-
creatic cancer and warrants additional study.
Methods
Blood samples using standard operating procedures were
obtained from pre-surgical resection (resectable) or by-pass
(advanced) patients with histologically confirmed PDAC,
histologically confirmed chronic pancreatitis (CP), benign
biliary obstruction (BBO) or from healthy controls (HC).
Resectable PDAC patients had normal tissue plane between
tumour and vessels and no evidence of metastatic disease
or tumour abutment less than 180° of the SMA or coeliac
axis, venous involvement up to 2 cm occlusion of the SMV,
PV or SMV-PV confluence with no evidence of metastatic
disease [42-44]. All patients gave written informed consent
using approved ethics protocols, at the Royal Liverpool
University Hospital.
Serum collection
Blood was collected in Sarstedt Monovette Serum Z
tubes (Sarstedt Ltd, Leicester, UK) and allowed to coagu-
late for 30 minutes before centrifugation at 800 × g for
10 min. The serum fraction was aliquotted into cryo-
tubes and stored at −80°C. CA19-9 levels were measured
using ELISA (Human Pancreatic & GI Cancer ELISA
Kit, Alpha Diagnostics International, San Antonio, Tx,
USA). Pre-operative total serum bilirubin (μmol/L)
(Roche Modular SWA) was measured in the hospital
Clinical Biochemistry Department.
Measurement of cytokines
The serum levels of 27 cytokines, chemokines and
growth factors from patients and healthy subjects were
measured blindly in duplicate using a commercially
available Bio-Plex Pro 27 Plex Human Cytokine, Chemo-
kine and Growth Factor Assay (Bio-Rad Laboratories
Ltd, Hercules, CA, USA), on the Bio-Plex 200 System,
with initial data analysis to measure concentration per-
formed using Bio-Plex Manager 5.0 Software. Briefly,
serially diluted standards (50 μL) and test serum, diluted
1 in 4 in sample diluent, (50 μl) was added to a microfil-
ter plate containing antibody-coupled beads for each of
the 27 analytes. The microfilter plate was incubated at
room temperature on a plate shaker at 900 rpm for 1 mi-
nute followed by 300 rpm for 30 minutes. Followingwashing by vacuum filtration the secondary antibodies
(25 μL) were added and the microfilter plate incubated
as before. The microfilter plate was washed again and
Streptavidin-PE (50 μL) was added and the plate incu-
bated at room temperature on a plate shaker at 900 rpm
for 1 minute followed by 300 rpm for 15 minutes. Assay
buffer (125 μL) was added to each well of the microfilter
plate before being read on the Bio-Plex 200 machine.
Fluorescent intensities obtained for the test samples
were read from the standard curve to give pg/mL values
for each of the 27 cytokines, chemokines and growth
factors. Ten assay plates were used to generate training
data from 158 individuals, and test data from 83 individ-
uals. To assess inter-plate variation, 6 individual samples
were measured across triplicate plates; and at least one
aliquot of the same PDAC patient was assayed on every
plate for internal control purposes.
Patient groups
The training set consisted of samples from 158 subjects,
84 patients with PDAC, 45 patients with benign pancre-
atic disease (32 with CP and 13 with BBO due to gall
stones) and 29 HCs. The serum bilirubin level of pa-
tients was recorded in all cases as either low (<20 μmol/
L; upper level of normal for our Centre) or high
(>20 μmol/L). In the training set there were 73 (46.2%)
patients with high bilirubin, 55 with PDAC and 18 with
BBO including 5 with CP. The independent test set con-
sisted of samples from 83 subjects, 43 patients with
PDAC, 17 with CP, 7 with BBO, and 16 HCs. In the test
set there were 37 (44.6%) patients with high bilirubin, 28
with PDAC and 9 patients with BBO (including 2 with
CP). The clinical characteristics of the training and test
study populations are provided in Table 3, with further
specific characteristics of cancer patients, separated
into resectable and advanced categories, provided in
Additional file 2: Table S2. The median age of healthy
control subjects in the training set was 44 years com-
pared to a median age of 66 years for the PDAC pa-
tients and the median age of healthy control subjects in
the test set was higher at 56.5 years.
Data filtering, normalisation
Cytokines with internal control measurements with a coef-
ficient of variance > 50% were removed from the dataset.
Cytokine concentrations (pg/mL) less than the lower limit
of detection were set to 0.001. The remaining cytokines,
along with CA19-9, were used in predictor model building.
Normalisation between plates was undertaken by dividing
raw cytokine data by the plate-specific internal control
value for each cytokine. Normalised data were log2 trans-
formed for statistical analysis. The Shapiro-Wilk test with
cut-off of p < 0.05 was applied to test the null hypothesis
that data were normally distributed. Two-sample Wilcoxon











PDAC (n = 84) 66 (64.0-69.0) 47:37 137.5 (62.0-161.4) 31 (24.5-54.3)
CP (n = 32) 53 (48.0-58.6) 20:12 24.5 (11.0-41.0) 7 (6.0-10.0)
BBO (n = 13) 72 (60.7-77.4) 11:2 89 (13.5-228.3) 69 (11.0-108.6)











PDAC (n = 43) 68 (64.2-71.8) 24:19 116 (54.9-164.4) 51 (19.6-114.0)
CP (n = 17) 53 (45.1-62.0) 10:7 12 (8.0-24.9) 6 (5.0-10.0)
BBO (n = 7) 64 (38.4-78.5) 3:4 37 (4.5-181.3) 100 (44.9-374.9)
HC (n = 16) 56.5 (36.7-62.1) 9:7 3 (2.6-8.4) NA
PDAC = Cancer, CP = Chronic Pancreatitis, BBO = Benign Biliary Obstruction, HC = Healthy Controls.
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0.05 were applied to test the null-hypothesis that the me-
dians of groups with non-parametric (non-normal) distri-
bution were the same. Following normalisation and log2
transformation, the class labels (e.g. PDAC, CP, BBO or
HC) were added to the data set.
Building statistical predictor models
Statistical modelling was performed in 64-bit R (2.15.1;
R Development Core Team 2012). The training dataset
was used to construct binomial logistic models, using
the R function glm, to discriminate the following patient
groups: PDAC versus HC; PDAC versus Benign Disease
(combined CP and BBO patients) PDAC versus CP and
PDAC in the presence of jaundice versus Benign Disease
in the presence of jaundice.
Cytokines for inclusion in models were selected using re-
peated (n = 100) balanced splitting of the training set, tabu-
lating the optimal cytokine panel for each model and then
ranking cytokines. Feature finding at each data split was
performed by complete enumeration of all possible logistic
regression models by Morgan-Tatar search, selecting the
highest ranked model as scored by Bayesian information
criterion using the bestglm package in R. Cytokines were
selected if they achieved a regression p < 0.05 in the top
ranked model. Logistic predictor models fitted to data in
this way consisted of a probability function (i.e. a predictor
of class membership) of the form exp(z)/1 + exp(z) where z
is a specific linear combination of coefficients, such that
z = β0 + β1x1 + β2x2…, where βi are cytokine specific coeffi-
cients found by regression (βo being the intercept) and xi
are sample cytokine specific values. Classification perform-
ance was assessed by Receiver Operating Characteristic
(ROC) analysis using the pROC [45] and ROCR [46] pack-
ages from R to find the optimum sensitivity (SN), specificity
(SP) and Area Under Curve (AUC). Comparisons of AUCs
of cytokine panel models versus CA19-9 alone were per-
formed using a one-tailed De Long’s test. The classificationperformance of models developed with the training data
was assessed by internal validation and independently using
the test set data. Confidence intervals (95%) for the SN and
SP of individual diagnostic tests were calculated as exact bi-
nomial proportion intervals using the R package epiR. The
McNemar test was used to compare SN and SP of paired
diagnostic tests using the R package DTComPair [47].
Resampled estimates of model performance
The robustness of the classification models developed with
training data was evaluated by repeatedly resampling data
from the combined training and test cohorts. The com-
bined dataset was split randomly 100 times at a ratio of 2
to 1 into resampled training and test sets, taking care to
maintain the proportionate class composition of the
resampled training and test sets (i.e. the ratio of cancer:
control). At each split, the resampled training dataset was
used to build a classification model using the cytokine panel
identified during binomial logistic modelling of the original
training sets. The ability of each model to classify the
resampled test data was recorded. ROC analysis was per-
formed and the SN and SP values, at the optimum accur-
acy, of each resampled test set were recorded. Thus, each
resampled model generated 100 independent estimates of
SN, SP at optimised accuracy, which were used to calculate
median SN/SP and median accuracy values. Since the
distribution of prediction error of resampled models was
non-normal and prediction errors with the same test set
but different models are not independent, the null hypoth-
esis of equality of prediction error distribution of different
models was tested using the Friedman test.
Additional files
Additional file 1: Table S1. Circulating cytokine levels in the combined
training and test datasets.
Additional file 2: Table S2. Patient characteristics of Resectable and
Advanced PDAC patients.
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